Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

By sjmartinez • April 18, 2024

Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18. PMID: 38632977.

Tags: Biologics, Dermatology, interleukin-23, psoriatic arthritis, Publications, risankizumab

Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review

Passero L, Simon TA, Zhong Y, Zhuo J, Varga S, Armstrong AW. Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic[...]

Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination

Wang J, Patel S, Kolker S, Bennett RG. Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination. Dermatol Surg. 2025 Dec[...]

Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis

Yan MJ, Jiang YC, Wongvibulsin S, Chen ST. Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis. JID Innov. 2025 Nov 17;6(2):100435.[...]